Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Esketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Delic Corp
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SPRAVATO® (esketamine) CIII nasal spray is a nonselective, noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor – an ionotropic glutamate receptor.
Brand Name : Spravato
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
Lead Product(s) : Esketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Delic Corp
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?